Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
Call for proposals The NOMIS Foundation and the Institute of Science and Technology Austria (ISTA) have launched an interdisciplinary basic research program for exceptional postdoctoral scientists
-
The call for applications for the ISTA-Fellow Postdoctoral Program is open! Are you eager to perform cutting-edge research in an international environment? Do you want to push the frontiers
-
Join Dr. Marcel van den Brink’s multidisciplinary team to explore innovative ways to decipher the molecular mechanisms by which the microbiome contributes to the biology of bone marrow transplantation. We are looking for a highly motivated candidate with a PhD degree interested in using...
-
The newly established Program for Memory Longevity (PML), led by Attila Losonczy, MD, PhD, in the O’Donnell Brain Institute (OBI) and the Department of Neuroscience at the University of Texas
-
The SQUASH Program is a prestigious Marie Skłodowska-Curie COFUND initiative offering 3-year postdoctoral positions in quantum science and technology. This 1st international call invites outstanding
-
ROSETTA is an innovative fellowship programme co-ordinated by the University of Galway and will involve four other universities (Implementing Partners): University College Cork , University College
-
Postdoctoral Research Fellows Air Force Science & Technology Fellowship Program The National Academies of Sciences, Engineering, and Medicine maintain a database of more than 300 research
-
, driving cutting-edge research at the intersection of metabolomics, human health, and toxicology. This exciting role offers the opportunity to contribute to major EU-funded research programmes, including
-
to formulate and lead a research programme that will deliver innovative, world-class science in molecular host-microbes interactions or a related field and good knowledge of JIC/NRP research fields, underpinning
-
oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor prognosis, and this clinic